Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 + Chemotherapy as Neoadjuvant Therapy for Unresectable Stage III NSCLC
NCT07408635Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI363 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jan 2026; status: recruiting.
02
Drugs
IBI363
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07408635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408635.